Back to search results

Co-Tox Study: E-cigarette and Cannabis Use in Young Adults

This observational study, called the Co-Tox Study, is looking at how young adults (ages 18-25) use e-cigarettes and cannabis. Researchers want to understand the levels of nicotine, cannabis, and harmful substances (toxicants) in the blood and urine of people who use these products. They will also look at your self-reported habits around using e-cigarettes and cannabis. This study aims to find differences in these levels and behaviors based on how you use these products, which will help plan larger studies in the future. The study is currently recruiting 150 participants.

Study design
This is an observational study with 150 planned participants. It will compare differences in biomarker levels across groups.
What's involved
You will complete a screening survey, choose a study completion location, and attend one study session lasting one hour. You will also answer questionnaires about your cannabis and e-cigarette use.
Compensation
Not stated in the trial record.
Follow-up
Biomarker levels will be measured at one study session. No further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07167225

Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use Cigarettes, E-cigarettes and Cannabis (Co-Tox Study)

Recruiting
Not specifiedAges 18–25Observational
Roswell Park Cancer Institute
~150 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:Effectiveness of different recruitment approachesChoice of study completion locationsCannabis Engagement AssessmentE-cigarette dependence ScaleNicotine dependence ScaleCo use practices QUestionnaire

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Differences in biomarker levels across groups
Measured over 1 study session lasting 1 hour

Conditions

Cigarette Smoking-Related Carcinoma
E-Cig Use

Explore related trials

Cigarette Smoking-Related CarcinomaVaping

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Danielle Smith, PhD · PRINCIPAL_INVESTIGATOR · Roswell Park

Who to contact

ASK RPCI
[email protected]
1-800-767-9355
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Young adult (18-25 years old).
Ability to read and write in English.
Participants must fall into one of the following groups (based on self-report):
Predominant e-cigarette consumer: defined as using nicotine-containing e-cigarettes daily for the past six months but not having used other nicotine containing products more than weekly or cannabis products for the past month.
Predominant cannabis consumer: defined as using cannabis at least 3x/week for the past six months in any form, including smoking, vaping, and oral use, with no more than weekly use of any nicotine or tobacco products.
E-cigarette-cannabis co-consumers: defined as daily use of nicotine e-cigarettes and use of cannabis at least 3x/week, including smoking, vaping, and oral use, for at least the past six months, with no use of other nicotine containing products more than weekly
Predominant cigarette consumers: defined as using cigarettes at least daily for the past six months, but not have used other nicotine-containing products more than weekly or cannabis products for the past month
Predominant cigarette-cannabis co-consumers: defined as those reporting daily cigarette use and use of cannabis at least 3x/week (including smoking or vaping) for at least the past six months, with no more than weekly use of other nicotine-containing products
No self-reported diagnosis of kidney disease (current, or within the past year prior to the study visit).
Participants must understand the voluntary nature of this study and sign a written informed consent form before proceeding with study activities.

Exclusion

Individuals under the age of 18 or over the age of 25.
Currently pregnant or breastfeeding (female participants).
Unwilling or unable to follow protocol requirements

What this trial measures

  • Differences in biomarker levels across groups1 study session lasting 1 hour

    Will compare the mean biomarker levels between groups using a one-way ANOVA model, with Bonferroni-adjusted pairwise comparisons, as appropriate.